Centers for Disease Control and Prevention Enhanced Surveillance for New Vaccine Preventable Diseases Solicitation for FY2017 | RFA IP16 00402CONT17

Opportunity Information: Apply for RFA IP16 00402CONT17

The FY2017 "Centers for Disease Control and Prevention Enhanced Surveillance for New Vaccine Preventable Diseases" opportunity (Funding Opportunity Number RFA IP16 00402CONT17) is a continuation cooperative agreement administered by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention (CDC). As a continuation action, it is designed to extend or maintain ongoing work rather than launch an entirely new, open-ended competition. The focus sits within the health activity category and is tied to CFDA 93.185, which generally aligns with CDC immunization and vaccine-related public health work. The solicitation was created on March 2, 2017, and had an original closing date of April 24, 2017, indicating a defined FY2017 application/continuation window for recipients positioned to carry the work forward.

At its core, the program supports enhanced public health surveillance for "new" vaccine-preventable diseases, meaning diseases that have recently become preventable through vaccines, are emerging as vaccine targets, or require improved monitoring as vaccine policy, recommendations, or products evolve. Enhanced surveillance typically goes beyond routine case reporting by strengthening the ability of jurisdictions and partner entities to find cases, confirm diagnoses, characterize disease severity, track trends over time, and understand who is being affected and why. In practice, this kind of work often involves improvements in case detection and investigation, more complete and timely reporting, better laboratory confirmation and typing, stronger linkage of epidemiologic and laboratory data, and closer integration of vaccination history and outcomes to evaluate vaccine impact in real-world settings.

The award instrument is a cooperative agreement, which signals that CDC expects to have substantial involvement in the funded activities rather than simply providing funds with minimal federal interaction. Cooperative agreements commonly include close technical collaboration, alignment with CDC surveillance standards, participation in CDC-led meetings or workgroups, adoption of common case definitions and data elements, and ongoing performance monitoring. This structure is typically used when CDC anticipates the need for coordinated national data, consistent methodologies across multiple awardees, and shared analytic approaches so that surveillance outputs can be compared or combined across jurisdictions.

The opportunity anticipated up to 10 awards, suggesting a networked model in which multiple recipients contribute data and operational capacity that feed into a broader national understanding of disease burden and vaccine performance. While the award ceiling is listed as 0, that generally indicates the posting did not specify a maximum award amount in the public summary field, not that awards would be unfunded. Actual funding levels in cooperative agreements often vary by recipient scope, population size, infrastructure needs, and specific surveillance responsibilities, and are typically detailed in the full notice or in continuation award documentation.

Eligibility is described as "Others (see text field entitled Additional Information on Eligibility for clarification)," which implies that the detailed eligibility rules were provided in the full announcement rather than in the brief summary. For CDC surveillance cooperative agreements, eligible entities often include state and local health departments, territorial health agencies, tribal entities, academic or nonprofit partners, and sometimes specific institutions with demonstrated capacity for surveillance, laboratory support, and data management. In continuation solicitations, eligibility is frequently limited in practice to existing recipients or a defined cohort of previously funded partners, consistent with the "continuation" category.

Overall, the grant opportunity is best understood as CDC support to sustain and enhance a coordinated surveillance system for vaccine-preventable diseases that require heightened monitoring. The expected outputs usually include more complete and higher-quality surveillance data, improved timeliness of reporting, stronger laboratory and epidemiologic integration, and analytic findings that help CDC and public health partners evaluate vaccine impact, detect changes in disease epidemiology, inform recommendations, and respond to outbreaks or shifts in transmission patterns. By funding multiple awards under a cooperative framework, CDC can ensure that surveillance methods are harmonized and that resulting data are useful for national-level situational awareness and policy decision-making.

• The Department of Health and Human Services, Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Centers for Disease Control and Prevention Enhanced Surveillance for New Vaccine Preventable Diseases Solicitation for FY2017" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.185.
• This funding opportunity was created on Mar 02, 2017.
• Applicants must submit their applications by Apr 24, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA IP16 00402CONT17

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: